This showed that the main reason for ALK+ NSCLC patients missing subsequent treatments, either TKI or chemotherapy, was rapid clinical deterioration (n=40/43 or 93%, Figure 4). This evidence concerns the gene ALK and non-small cell lung carcinoma.